Published in World J Gastroenterol on May 28, 2013
Diffusion-weighted magnetic resonance application in response prediction before, during, and after neoadjuvant radiochemotherapy in primary rectal cancer carcinoma. Biomed Res Int (2013) 0.84
Neoadjuvant chemoradiotherapy for locally advanced rectal cancer: The debate continues. World J Gastrointest Oncol (2014) 0.80
Clinical predictive factors of pathologic complete response in locally advanced rectal cancer. Oncotarget (2016) 0.78
Prognostic value of c-FLIPL/s, HIF-1α, and NF-κβ in stage II and III rectal cancer. Virchows Arch (2014) 0.77
Preoperative chemoradiotherapy in elderly patients with locally advanced rectal cancer. Biomed Res Int (2013) 0.76
Pre- and post-surgery treatments in rectal cancer: a long-term single-centre experience. Curr Oncol (2017) 0.75
Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med (2004) 25.68
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med (2004) 18.93
Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med (2006) 12.50
Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med (2000) 7.62
Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol (2010) 7.29
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol (2006) 7.05
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol (2011) 5.00
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer. J Clin Oncol (2006) 3.24
Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg (2006) 3.19
Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol (1999) 2.67
Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol (2010) 2.28
No downstaging after short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol (2001) 2.20
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. Ann Oncol (2005) 1.95
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol (2011) 1.54
Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst (2012) 1.39
Total mesorectal excision for middle and lower rectal cancer: a single institution experience with 337 consecutive patients. J Surg Oncol (2004) 1.31
Definition of total mesorectal excision, including the perineal phase: technical considerations. Dig Dis (2007) 1.24
Total mesorectal excision for surgical treatment of rectal cancer. J Surg Oncol (2000) 1.17
The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC). Eur J Cancer (2005) 1.05
Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res (2007) 1.04
Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer. J Surg Oncol (2007) 1.02
Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. Ann Surg Oncol (2007) 0.91
A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer. Cancer Lett (2011) 0.86
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study. Strahlenther Onkol (2011) 0.85
Preoperative intensified radiochemotherapy for rectal cancer: experience of a single institution. Int J Colorectal Dis (2010) 0.84
Neo-adjuvant treatment of rectal cancer with capecitabine and oxaliplatin in combination with radiotherapy: a phase II study. Ann Oncol (2009) 0.84
Is it time for tailored treatment of rectal cancer? From prescribing by consensus to prescribing by numbers. Radiother Oncol (2011) 0.83
[Rectal cancer: current status of multimodal therapy--when and how?]. Zentralbl Chir (2011) 0.80
Incidence of thromboembolic events in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. Acta Oncol (2012) 0.78
[Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies]. Cancer Radiother (2011) 0.77
Prostate cancer recurrence after radical prostatectomy: the role of 3-T diffusion imaging in multi-parametric magnetic resonance imaging. Eur Radiol (2013) 1.60
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer (2010) 1.16
MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Mol Cancer Ther (2011) 1.05
Texture analysis as imaging biomarker of tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance. Invest Radiol (2015) 0.96
Buschke-Löwenstein tumor with squamous cell carcinoma treated with chemo-radiation therapy and local surgical excision: report of three cases. World J Surg Oncol (2013) 0.95
Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. Endocrinology (2011) 0.92
Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models. Prostate (2014) 0.92
Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro Oncol (2012) 0.91
Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. Int J Oncol (2011) 0.90
Bilateral risk-reduction mastectomy in BRCA1 and BRCA2 mutation carriers: a meta-analysis. Ann Surg Oncol (2015) 0.87
Effects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro. Prostate (2009) 0.87
Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells. Prostate (2008) 0.86
PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer. Endocr Relat Cancer (2013) 0.85
Diffusion-weighted magnetic resonance application in response prediction before, during, and after neoadjuvant radiochemotherapy in primary rectal cancer carcinoma. Biomed Res Int (2013) 0.84
Preoperative intensified radiochemotherapy for rectal cancer: experience of a single institution. Int J Colorectal Dis (2010) 0.84
The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells. Endocr Relat Cancer (2011) 0.84
Chemoradiation as definitive treatment for primary squamous cell cancer of the rectum. World J Radiol (2010) 0.84
5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Prostate (2010) 0.83
MRI characterization of residual mediastinal masses in Hodgkin's disease: long-term follow-up. Magn Reson Imaging (2004) 0.83
Hypofractionated radical radiotherapy in elderly patients with medically inoperable stage I-II non-small-cell lung cancer. Lung Cancer (2010) 0.83
TRUS staging and follow-up in patients with anal canal cancer. Radiol Med (2003) 0.81
Irradiated fields spared Stevens-Johnson syndrome in a patient undergoing radiotherapy for bone metastases. Jpn J Radiol (2009) 0.81
New mutations and protein variants of NBS1 are identified in cancer cell lines. Genes Chromosomes Cancer (2003) 0.81
Antitumor effects of carnertinib in castration resistant prostate cancer models: a comparative study with erlotinib. Prostate (2011) 0.81
Complete response and long-term survival in malignant pleural mesothelioma: case report. Anticancer Res (2012) 0.81
Patterns of practice and survival in a retrospective analysis of 1722 adult astrocytoma patients treated between 1985 and 2001 in 12 Italian radiation oncology centers. Int J Radiat Oncol Biol Phys (2006) 0.81
Radiation therapy in the treatment of HIV-related Kaposi's sarcoma. Anticancer Res (2013) 0.80
Late morbidity and oncological outcome after radical hypofractionated radiotherapy in men with prostate cancer. BJU Int (2010) 0.80
Bicalutamide demonstrates biologic effectiveness in prostate cancer cell lines and tumor primary cultures irrespective of Her2/neu expression levels. Urology (2009) 0.80
Neoadjuvant chemoradiation for locally advanced carcinoma of the rectum. Tumori (2004) 0.80
Transrectal ultrasound color Doppler in the evaluation of recurrence of anal canal cancer. Eur J Radiol (2003) 0.79
Helical tomotherapy: an innovative radiotherapy technique for the treatment of locally advanced oropharynx and inoperable oral cavity carcinoma. Radiat Oncol (2013) 0.79
Low cell dosage of lymphoblastoid human cell lines EBV(+) is associated to chronic hepatitis in a minority of inoculated Nu/Nu mice. J Med Virol (2002) 0.79
Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck. J Immunother (2008) 0.79
Carcinoma of the vulva: clinical results of exclusive and adjuvant radiotherapy. Anticancer Res (2005) 0.79
Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review. Radiat Oncol (2014) 0.79
Advances in imaging and in non-surgical salvage treatments after radiorecurrence in prostate cancer: what does the oncologist, radiotherapist and radiologist need to know? Eur Radiol (2012) 0.79
Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study. Pancreas (2009) 0.78
Epigenetic modulation of PTEN expression during antiandrogenic therapies in human prostate cancer. Int J Oncol (2009) 0.78
Incidence of thromboembolic events in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. Acta Oncol (2012) 0.78
Close correlation between MEK/ERK and Aurora-B signaling pathways in sustaining tumorigenic potential and radioresistance of gynecological cancer cell lines. Int J Oncol (2013) 0.77
High-grade gliomas: results in patients treated with adjuvant radiotherapy alone and with adjuvant radio-chemotherapy. Anticancer Res (2006) 0.77
Metabolic atrophy and 3-T 1H-magnetic resonance spectroscopy correlation after radiation therapy for prostate cancer. BJU Int (2014) 0.77
The inhibition of p85αPI3KSer83 phosphorylation prevents cell proliferation and invasion in prostate cancer cells. J Cell Biochem (2013) 0.77
Intravesical instillations with polydeoxyribonucleotides reduce symptoms of radiation-induced cystitis in patients treated with radiotherapy for pelvic cancer: a pilot study. Support Care Cancer (2013) 0.76
Multiple bone metastases from glioblastoma multiforme without local brain relapse: a case report and review of the literature. Tumori (2013) 0.76
Pain evaluation and management: a survey of Italian radiotherapists. Support Care Cancer (2004) 0.75
Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case report. Medicine (Baltimore) (2017) 0.75
Low-dose fotemustine as second-line chemotherapy for recurrent glioblastoma multiforme. Anticancer Res (2013) 0.75
An unusual case of fatty liver in a patient with desmoid tumor. World J Gastroenterol (2012) 0.75
Prognostic implications of node metastatic features in OSCC: a retrospective study on 121 neck dissections. Oncol Rep (2013) 0.75
Radiotherapy in the treatment of stage III-IV hypopharyngeal carcinoma. Anticancer Res (2004) 0.75
Strategies for imaging androgen receptor signaling pathway in prostate cancer: implications for hormonal manipulation and radiation treatment. Biomed Res Int (2013) 0.75
Definitive Chemoradiotherapy for Anal Carcinoma: Long-Term Results Based on Consistent Time-to-Event Endpoints. Oncology (2017) 0.75
Radiotherapy and sequential temozolomide compared with radiotherapy with concomitant and sequential temozolomide in the treatment of newly diagnosed glioblastoma multiforme. Anticancer Drugs (2006) 0.75
Recurrent Ovarian Cancer: The Role of Radiation Therapy. Int J Gynecol Cancer (2017) 0.75
Basosquamous or Basal Cell Carcinoma? The Importance of the Differential Diagnosis. J Craniofac Surg (2015) 0.75
Dose-finding study of docetaxel added to ifosfamide and cisplatin followed by concomitant capecitabine and radiotherapy in the treatment of locally advanced squamous cell carcinoma of the head and neck. Anticancer Res (2006) 0.75
Oral Platelet Gel Supernatant Plus Supportive Medical Treatment Versus Supportive Medical Treatment in the Management of Radiation-induced Oral Mucositis: A Matched Explorative Active Control Trial by Propensity Analysis. Am J Clin Oncol (2017) 0.75
Radiotherapy alone and chemoirradiation in recurrent squamous cell carcinoma of the vulva. Anticancer Res (2003) 0.75
Number of mediastinal lymph nodes as a prognostic factor in PN2 non small cell lung cancer: a single centre experience and review of the literature. Asian Pac J Cancer Prev (2014) 0.75
Bevacizumab in Ovarian Cancer: State of the Art and Unanswered Questions. Chemotherapy (2016) 0.75
Prolonged disease control after myeloablative chemotherapy, autologous transplantation and immunotherapy in high-risk early breast cancer. Anticancer Res (2010) 0.75
Postoperative radiotherapy with volumetric modulated arc therapy of lacrimal gland carcinoma: two case reports and literature review. Future Oncol (2014) 0.75
Comparison between intensified neoadjuvant treatment and standard preoperative chemoradiation for rectal cancer. Tumori (2010) 0.75
New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors. Curr Cancer Drug Targets (2017) 0.75
The Addition of Target Therapy to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer: A Review. Chemotherapy (2017) 0.75
Short-Infusion Trabectedin in Heavily Pretreated Ovarian Cancer Patients: A Single-Institution Experience. Oncology (2017) 0.75
Pulsed-Dose Rate Brachytherapy for the Treatment of Endometrial Cancer. Oncology (2017) 0.75
Chyle Leak Following Neck Dissection: Could Radiotherapy Be Considered a Management Option? J Craniofac Surg (2016) 0.75
Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damage. Oncotarget (2016) 0.75